Search Results
Your search for ,amp matches 4215 pages
Showing 3251 - 3300Parents May be More Likely to Support HPV Vaccine Requirements for School Entry If States Include Opt-Out Provisions
Parents are more likely to support laws that would make the human papillomavirus (HPV) vaccine mandatory for school entry if their state offers opt-out provisions, according to a study published by Calo et al in Cancer Epidemiology, Biomarkers & Prevention. However, opt-out provisions may...
Study Finds United States Ranks First in Health-Care Spending, but Cancer Outcomes Do Not Reflect the Investment
The U.S. health-care system is characterized—on a global level—by its unsustainable spending, which does not necessarily correlate to better outcomes in patients with cancer. With $2.9 trillion spent in 2013, the United States ranks first in health-care spending among the world’s...
Pancreatic Cancer Action Network Appoints Four Leaders to Its Scientific and Medical Advisory Board
The Pancreatic Cancer Action Network has added four leaders from across the country to its Scientific and Medical Advisory Board. “Members of the Pancreatic Cancer Action Network Scientific and Medical Advisory Board have committed their careers to change the course of a deadly and complex...
NCCN Imaging Appropriate Use Criteria to Be Integrated Into National Decision Support Company’s CareSelect Imaging
The National Comprehensive Cancer Network® (NCCN) is collaborating with National Decision Support Company (NDSC) to integrate the NCCN Imaging Appropriate Use Criteria (AUC) into NDSC’s CareSelect Imaging to allow for access to imaging recommendations, adapted from the NCCN Clinical Practice...
2016 - 2017 Oncology Meetings
AUGUST The 33rd World Congress of Internal Medicine (WCIM)August 22-25 • Bali, IndonesiaFor more information: www.wcimbali2016.org 16th World Congress on Cancers of the SkinAugust 31-September 3 • Vienna, Austria For more information: www.wccs2016.com 12th National Lymphedema Network International...
ASCO and CancerLinQ Participated in Landmark Cancer Moonshot Summit
ASCO Chief Executive Officer Clifford A. Hudis, MD, FASCO, and CancerLinQ LLC Chief Executive Officer Kevin Fitzpatrick attended Vice President Joe Biden’s Cancer Moonshot Summit at Howard University on Wednesday, June 29, 2016. Along with leaders and stakeholders across the cancer research and...
Recommendations for Surveillance of Premature Ovarian Insufficiency in Female Survivors of CAYA Cancers
Harmonized recommendations for surveillance of premature ovarian insufficiency in female survivors of childhood, adolescent, and young adult (CAYA) cancers have been published by van Dorp et al in the Journal of Clinical Oncology on behalf of the International Late Effects of Childhood Cancer...
Poorer Outcome in Favorable-Histology Wilms Tumor Associated With Chromosome 1q Gain Reported in U.S. Study
The Children’s Oncology Group found that chromosome 1q gain is associated with poorer event-free and overall survival in patients with favorable-histology Wilms tumor. Gratias et al reported these findings in the Journal of Clinical Oncology. Study Details The study involved analysis of...
FDA Grants Breakthrough Therapy Designation for Daratumumab in Combination With Standard of Care for Multiple Myeloma
The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to the immunotherapy daratumumab (Darzalex) in combination with lenalidomide (Revlimid) and dexamethasone, or bortezomib (Velcade) and dexamethasone, for the treatment of patients with multiple myeloma who have ...
Rajesh K. Garg, MD, JD, Named President, CEO of CTCA
Rajesh K. Garg, MD, JD, is now President and CEO of Cancer Treatment Centers of America Global, Inc (CTCA). The announcement was made by CTCA earlier this spring. Dr. Garg, who started this new position on June 20, 2016, will also serve as a member of the company’s national Board of Directors. Dr. ...
The Healing Power of Words
Feminist literary scholar Susan Gubar was diagnosed with advanced ovarian cancer in November 2008. She then began her emigration “from the world of the healthy to the domain of the ill,” she wrote in her acclaimed book, Memoir of a Debulked Woman: Enduring Ovarian Cancer. In her memoir, she...
2016-2017 Oncology Meetings
AUGUST Palliative Medicine and Supportive Oncology 2016August 3-6 • Cleveland, OhioFor more information:www.clevelandclinicmeded.com/live/courses/pallmed/default.asp 17th Annual International Lung Cancer Congress®August 4-6 • Huntington Beach, CaliforniaFor more information:...
ASCO Outlines Opposition to Medicare Part B Demo for Senate Finance Hearing
ASCO voiced its strong opposition to the proposed Medicare Part B demonstration project in comments submitted on June 28 for the U.S. Senate Finance Committee hearing, “Examining the Proposed Medicare Part B Drug Demonstration.” ASCO underscored the urgent need to advance a fairer and more...
As Low-Dose CT Screening Moves Into the Clinic, Implementation Issues Move Up on the Agenda
Low-dose computed tomography (CT) screening for lung cancer in high-risk groups is moving into the clinic in the wake of its approval by the U.S. Centers for Medicaid & Medicare Services. That does not mean, however, the discussion is over. As low-dose CT moves from research to everyday...
Lung Cancer Screening: Beneficial for Certain Populations but Not Without Controversy
The National Cancer Policy Forum of the National Academies of Sciences took up the issue of lung cancer screening at its mid-June workshop. Greta Massetti, PhD, Associate Director for Science, Division of Cancer Prevention and Control, Centers for Disease Control and Prevention (CDC), and chair of ...
POLE Mutations in Colorectal Cancer May Identify Patients With a Better Prognosis
A collaboration between multiple European institutions has uncovered a correlation between a rare mutation in colorectal cancers and a better prognosis, raising the possibility that patients with such tumors may not require chemotherapy after surgery. Findings were published by Domingo et al in The ...
Five-Year Survival Data: Brentuximab Vedotin May Be Curative in Some Patients With Hodgkin Lymphoma
Five-year survival data published by Chen et al in Blood suggest that the targeted therapy brentuximab vedotin (Adcetris) may be curative in some patients with Hodgkin lymphoma whose disease has persisted despite receiving previous therapies. This multinational phase II study examined brentuximab...
ASCO Resolutions Supported by AMA House of Delegates
At the American Medical Association’s (AMA) annual House of Delegates meeting, delegates approved four resolutions submitted by ASCO, demonstrating the entire medical community’s commitment to key cancer care priorities. These resolutions have been incorporated into the AMA’s policy system and will ...
HHS Announces Physician Groups Selected for Initiative Promoting Better Cancer Care
The U.S. Department of Health and Human Services (HHS) has announced that it has selected nearly 200 physician group practices and 17 health insurance companies to participate in a care delivery model that supports and encourages higher quality and more coordinated cancer care. The Medicare arm of...
Expert Point of View: Patricia A. Ganz, MD & Gregory A. Masters, MD
“This is a tremendous advance. If we had a drug that could achieve these results we would rush to use it. This is also personalized medicine that alerts the health-care team when symptoms need addressing. And it is very important that using the app led to appropriate use of scans and tests, which...
Benefit Strongly Suggested With Hormonal Maintenance in Low-Grade Serous Carcinoma
In patients with low-grade serous carcinoma, maintenance hormonal therapy reduced the risk of recurrence by 77%, compared with surveillance, in a retrospective cohort from The University of Texas MD Anderson Cancer Center. The study was reported by David Marc Gershenson, MD, at the 2016 ASCO...
Studies Suggest Bright Future for Combination Immunotherapy in Advanced Melanoma, but Questions Remain
Two studies presented at the 2016 ASCO Annual Meeting focused on the use of combination immunotherapy in the treatment of patients with advanced melanoma. Updated results from the phase III CheckMate 067 trial centered on the combination of nivolumab (Opdivo) plus ipilimumab (Yervoy) compared...
CMS Proposal for Part B Drug Payment: A Poorly Conceived Experiment
On March 11, 2016, the Centers for Medicare & Medicaid Services (CMS) issued a proposed rule in the Federal Register to test a change in reimbursement for Part B drugs.1 The first phase involves changing the 6% add-on to the average sales price (ASP) used to make drug payments under Part B to...
Early Evidence of Anti–PD-1 Activity in Enzalutamide-Resistant Prostate Cancer
Restoring tumor-specific immunity is a treatment strategy that works well in melanoma and lung cancer patients. Now a new study out of the Oregon Health & Science University (OSHU) Knight Cancer Institute is reviving hope that the approach also may help men with life-threatening prostate...
Opportunistic Salpingectomy for Ovarian Cancer Prevention Adopted Without Adverse Surgical Outcomes
A surgical procedure recommended to reduce the future risk of ovarian cancer has been successfully implemented throughout Kaiser Permanente in Northern California without a change in surgical outcomes, according to research published by Garcia et al in Obstetrics & Gynecology. Previous...
Despite Increasing Global Legalization of Physician-Assisted Suicide, Use Remains Rare
Despite increasing legalization of euthanasia and physician-assisted suicide worldwide, the practices remain relatively rare and, when carried out, are primarily motivated by psychological factors such as loss of autonomy or enjoyment of life, rather than physical pain. A new comprehensive...
Survey Asks Women Whom They Trust Most When Selecting Breast Cancer Surgery and Reviews Postsurgical Satisfaction
A research team led by Rebecca M. Kwait, MD, Breast Health Fellow at The Breast Health Center at Women & Infants Hospital of Rhode Island, recently presented research indicating that when faced with a decision on the type of surgery to have for breast cancer, more women trust their own judgment ...
ASH and LLS Announce AML Awareness and Education Collaboration
The American Society of Hematology (ASH) and the Leukemia & Lymphoma Society (LLS) are teaming up to raise awareness and provide education about the need for new treatments for acute myeloid leukemia (AML). AML is a complex group of approximately 20 different types of blood cancers with a very...
2016 Oncology Meetings
JULY Pan Pacific Lymphoma ConferenceJuly 18-22 • Koloa, Hawaii For more information: www.unmc.edu/cce/catalog/clinicmed/panpacificlymphoma/index.html UK Breast Cancer Research SymposiumJuly 22-23 London, United Kingdom For more information: http://breastcancerconference.org Mayo Clinic Oncology...
Clinical Trials Actively Recruiting Patients With Cardiotoxicity Resulting From Treatment
Observational Study Title: Assessment for Long-Term Cardiovascular Impairment Associated With Trastuzumab Cardiotoxicity in HER2-Positive Breast Cancer Survivors Study Type: Observational Study Sponsor and Collaborators: Memorial Sloan Kettering Cancer Center Purpose: To study whether strain and...
Pertuzumab-Containing Regimens Compared for Neoadjuvant Treatment in Early Breast Cancer
In patients with HER2-positive early breast cancer, pathologic complete response rates after neoadjuvant therapy were higher with docetaxel plus carboplatin plus trastuzumab (Herceptin) plus pertuzumab (Perjeta), or TCH+P, than with ado-trastuzumab emtansine (Kadcyla) plus pertuzumab, or T-DM1+P,...
Women With High-Grade Cervical Intraepithelial Neoplasia Have Long-Term Increased Risk for HPV-Related Anal, Vulvar, and Vaginal Cancers
Although high-risk human papillomavirus (HPV) is essential for developing high-grade cervical intraepithelial neoplasia (CIN2 and CIN3) and has also been associated with noncervical anogenital cancers, little is known about the long-term risk for anal, vulvar, and vaginal cancer following a...
ASCO Outlines Opposition to Medicare Part B Demo for Senate Finance Hearing
ASCO voiced its strong opposition to the proposed Medicare Part B demonstration project in comments submitted on June 28 for the U.S. Senate Finance Committee hearing, “Examining the Proposed Medicare Part B Drug Demonstration.” ASCO underscored the urgent need to advance a fairer...
CAP, IASLC, and AMP Seek Public Comments on Revised Lung Cancer Molecular Testing Guideline
The College of American Pathologists (CAP), the International Association for the Study of Lung Cancer (IASLC), and the Association for Molecular Pathology (AMP) announced today the open comment period for the revised evidence-based guideline, “Molecular Testing Guideline for Selection of...
Influence of Microbiota of Breast Tissue on the Development of Cancers
Bacteria that have the potential to abet breast cancer are present in the breasts of cancer patients, while beneficial bacteria are more abundant in healthy breasts, where they may actually be protecting women from cancer, according to Gregor Reid, PhD, of the Lawson Health Research Institute, and...
A Journalist’s Cancer Saga
Readers of the recently published memoir A Series of Catastrophes & Miracles: A True Story of Love, Science, and Cancer find out that the book has a happy ending on the cover page of chapter 1. Spoiler: I lived, writes the author, Mary Elizabeth Williams, an acclaimed journalist with a list...
2016 Oncology Meetings
JULY The 5th International Inflammatory Breast Cancer ConferenceJuly 9-10 • Boston, MassachusettsFor more information:www.hmscmeregistration.org/events/breast-cancer-new-horizons-current-controversies/custom-21-857304c388f143b7840614d1bb151442.aspx 24th Biennial Congress of the European Association ...
Pembrolizumab Active in PD-L1–Positive Advanced Gastric Cancer and Triple-Negative Breast Cancer
The KEYNOTE-012 phase Ib trial assessed single-agent pembrolizumab (Keytruda) in patients with advanced programmed cell death ligand 1 (PD-L1)–positive gastric cancer, triple-negative breast cancer, urothelial cancer, and head and neck cancer. The activity of pembrolizumab in study patients with...
Cancer Treatment Centers of America Names Rajesh K. Garg, MD, JD, as President and CEO
Cancer Treatment Centers of America Global, Inc. (CTCA) has announced that Rajesh Garg, MD, JD, a highly regarded health-care industry leader with more than 25 years of experience across the health-care spectrum, will become its President and CEO. His appointment was effective June 20, 2016. He...
Adherence to Cancer Prevention Guidelines on Diet and Physical Activity May Reduce Cancer Risk and Mortality
According to the American Cancer Society’s 2016 Cancer Facts & Figures, behaviors such as poor diet choices, physical inactivity, excess alcohol consumption, and unhealthy body weight account for about 20% of all cancers diagnosed in the United States and likely could be prevented with...
Once-Daily Radiation (66 Gy) Appears No Better Than Twice-Daily Radiation (45 Gy) for Small Cell Lung Cancer
A schedule of once-daily radiation therapy (66 Gy) was no better than a twice-daily schedule (45 Gy) for optimization of chemoradiotherapy in patients with limited-stage small cell lung cancer (SCLC), according to the eagerly anticipated results of the phase III CONVERT trial, presented at the...
Matching Treatment to Tumor Abnormalities Seems to Pay Off
A strategy of matching molecular abnormalities in patients’ tumors to therapies targeted to those abnormalities is gaining ground, according to preliminary results of the phase IIb MyPathway study presented at the 2016 ASCO Annual Meeting.1 These are still early days for this “matching” strategy,...
Autologous Stem Cell Transplantation Offers Safe, Effective Option for Patients With HIV-Associated Lymphoma
A phase II, multicenter trial published by Alvarnas et al in Blood challenges the generally held belief that individuals with human immunodeficiency virus (HIV) and aggressive lymphoma are not candidates for standard treatment. According to the researchers, people with HIV-associated lymphoma who...
Study Finds Pembrolizumab Active in Advanced Head and Neck Cancer
As reported by Seiwert et al in The Lancet Oncology, the monoclonal antibody pembrolizumab (Keytruda) showed activity in patients with programmed cell death ligand 1 (PD-L1)–positive recurrent or metastatic squamous cell carcinoma of the head and neck in the phase Ib KEYNOTE-012 study. Study ...
The Best HCAHPS Score: A Rodeo Invitation
An otherwise healthy, actively working, independent 60-year-old patient came to us with a several months’ history of abdominal pain. He had been seen by other physicians prior to coming to us for a second opinion. Our workup revealed a large cystic lesion emanating from the pancreas but involving ...
Daratumumab Shows High Activity in Heavily Pretreated and Refractory Multiple Myeloma
In the phase II SIRIUS trial reported in The Lancet, Sagar Lonial, MD, of Winship Cancer Institute, Emory University, and colleagues found that the CD38-targeted monoclonal antibody daratumumab (Darzalex) produced durable responses in patients with multiple myeloma who had received at least three ...
Lung Cancer Alliance Supports Two Young Investigator Awards
The Conquer Cancer Foundation of ASCO (CCF) has received generous support from Lung Cancer Alliance to fund a 2016 and 2017 Young Investigator Award (YIA) in lung cancer. Lung Cancer Alliance has a more than 20-year history of working to save lives and advance research by empowering those living...
Combined-Modality Therapy for Low-Grade Gliomas: Balancing Toxicity, Delivery Logistics, and Survival Benefit
Low-grade gliomas account for 15% of all primary brain tumors and represent a heterogeneous group of glial neoplasms. Although these tumors have been termed low-grade, this is a misnomer, especially for some grade II gliomas, which may exhibit a more aggressive behavior and variable natural...
Ovarian Suppression in Premenopausal Women With Estrogen Receptor–Positive Breast Cancer
Oophorectomy was the first proposed form of endocrine therapy for women with breast cancer. Over 100 years ago, Thomas Nunn reported a relationship between menopause and regression of breast cancer.1 This incited interest in the induction of menopause as an anticancer therapy, and in 1986, a...
Dr. William Morton and His Engineer
A Century of Progress The text and photograph on this page are excerpted from a four-volume series of books titled Oncology Tumors & Treatment: A Photographic History, by Stanley B. Burns, MD, FACS. The photo below is from the volume titled “The Antiseptic Era: 1876–1900.” To view additional...
